Inhibrx Biosciences, Inc.
INBX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | -100% | – |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | – | 49.1% | – | -589% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -1,911.5% | – | -47,176% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -2,204.2% | – | -47,865% |
| EPS Diluted | -2.28 | -1.85 | -2.8 | -3.31 |
| % Growth | -23.2% | 33.9% | 15.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |